TCRR News and Press, TCR2 Therapeutics Inc. From 01/10/22

- Safety Review Team (SRT) identified gavo-cel recommended Phase 2 dose (RP2D) at 1x10 8 cells/m 2 - Initiation of gavo-cel Phase 2 study expected in 1H 2022 with initial data in 2H 2022 - Initial data from TC-510 Phase 1/2 trial anticipated in 2H 2022 - Selection of lead allo...

CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- https://investors.tcr2.com/ TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, today announced that Garry Men...

CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, today announced that Garry Menzel, President and Chief Exe...

CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, and Arbor Biotechnologies, a biotechnology company discovering and...

CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, today announced financial results for the third quarter ended Sept...

- Second clean room at ElevateBio BaseCamp will expand cGMP capacity for clinical trials in 2022 - Future network to focus on TCR 2 manufacturing center of excellence in Rockville, MD - Strategy optimizes efficiencies and simplifies regulatory pathway CAMBRIDGE, Mass., Nov. ...

CAMBRIDGE, Mass., Oct. 25, 2021 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced a clinical trial collaboration agreement with Bristol Mye...

- gavo-cel recommended Phase 2 dose (RP2D) identification before year-end - Anticipated IND filing for TC-510 in 1Q22 - Identification of CD70-targeted lead candidate - Anticipated allogeneic program lead candidate in 2022 - Expansion of platform into autoimmune diseases w...

CAMBRIDGE, Mass., Oct. 13, 2021 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that it will host a virtual R&D Day for analysts and invest...

Today, we are taking our first look at TCR Therapeutics since May of this year. The company continues to advance its early-stage pipeline, but the stock took a recent tumble after some interim trial results were posted. Time to buy the dip? A full investment analysis is prese...